Current & Future State Of Gene Therapy – Contract Pharma

Sheila Mikhail, CEO and Co-Founder of AskBio, was recently named EYs 2021 Entrepreneur Of The Year National Overall Award winner. The preeminent competitive awards recognize the unstoppable entrepreneurs transforming our world. Sheila is a business leader changing lives by advancing genetic technology and adeno-associated virus (AAV) Gene therapy. AskBios technology arms viruses with healthy biomaterial that rewrites disease-causing DNA mutations, significantly fortifying the frontline against cancer, muscular dystrophy and more. In her role as CEO, Sheila ensured AskBios gene trials continued through the pandemic, helping blind people see and giving children in wheelchairs the ability to walk and even play baseball. AskBio is a pioneer of AAV technology, which can be used as a delivery system for therapeutic genetic material into living tissues, curing disease. Bayer purchased the company in December 2020. Sheila discusses breakthroughs with gene therapies and the impact they've had on the industry, what we can expect for the Gene Therapy market going forward, and the challenges that remain.

Contract Pharma: What significant breakthroughs are you seeing with gene therapies?

CP: What impact have these had on the industry and advancing these therapies?

CP:What challenges remain with the development and manufacture of gene therapies? SM: While there has been tremendous progress made in gene therapy in recent years, there are still challenges we are working to solve.

CP: What do you anticipate for the gene therapy market going forward?

Excerpt from:
Current & Future State Of Gene Therapy - Contract Pharma